An Ionic Contrast Agent Inhibits Platelet-dependent Thrombin Generation and Boosts the Effect of Abciximab

Thromb Haemost 2001; 85(05): 944-945
DOI: 10.1055/s-0037-1615778

Letters to the Editor

Schattauer GmbH

Raed Al Died

¹Synapse Laboratories and Department of Cardiology, Cardiovascular Research Institute (CARIM), Universiteit Maastricht, The Netherlands

,

Ebo de Muinck

¹Synapse Laboratories and Department of Cardiology, Cardiovascular Research Institute (CARIM), Universiteit Maastricht, The Netherlands

,

Coenraad H. Hemker

¹Synapse Laboratories and Department of Cardiology, Cardiovascular Research Institute (CARIM), Universiteit Maastricht, The Netherlands

,

Suzette Béguin

¹Synapse Laboratories and Department of Cardiology, Cardiovascular Research Institute (CARIM), Universiteit Maastricht, The Netherlands

References
1 Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. The Lancet 1997; 349: 1429-35.
2 Béguin S, Kumar R, Keulerts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-70.
3 Grines CL, Schreiber TL, Savas V, Jones DE, Zidar FJ, Ganghadharan V, Brodsk M, Levin R, Safian R, Puchrowicz-Ochocki S, Castellani MD, O’Neill WW. A randomized trial of low osmolar versus non-ionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J. Am Coll Cardiol 1996; 27: 1381-6.
4 Davidson CJ, Laskey WJ, Hermiller JB, Harrison JK, Matthai W, Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW. Randomized trial of contrast media utilisation in high-risk PTCA; the COURT trial. Circulation 2000; 101: 2172-7.